SCHEMBL6322208

SCHEMBL6322208

CCOc1ccc(Br)c(I)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NQO1 P15559 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ APOBEC3G Q9HC16 1/20 0.42
▸ TP53 P04637 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ ESR2 Q92731 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CA12 O43570 2/20 0.40
▸ CA1 P00915 2/20 0.40
▸ CA7 P43166 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26635479 0.85 THRA (0.45) TSHRMEN1NPC1KMT2ACYP3A4
SCHEMBL17825436 0.85 CA12 (0.43) MEN1KMT2ATP53MAPTCA12
SCHEMBL9425356 0.81 NQO1 (0.56) NQO1KDM4ETSHRTDP1MEN1
SCHEMBL23887132 0.81 SMN1; SMN2 (0.35) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL30176397 0.81 SMN1; SMN2 (0.35) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL26635301 0.80 THRA (0.51) TSHRTP53LTA4H
SCHEMBL26635406 0.80 THRA (0.51) TSHRTP53LTA4H
SCHEMBL10763867 0.78 NPC1 (0.42) KDM4ETDP1NPC1MAPT
SCHEMBL11356998 0.78 NQO1 (0.43) NQO1KDM4ETSHRTDP1MEN1
SCHEMBL20556591 0.78 RARB (0.44) KDM4ETSHRTDP1MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050209278-A1 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors PHARMACIA CORPORATION 2005-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209278-A1 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors MMP1, PREP, MMP3 NQO1 1006/4885KDM4E 1152/4885TSHR 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback